Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis.<h4>Case report</h4>In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions.<h4>Conclusions</h4>IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Here, IL17A is linked to metabolic syndrome.